Data / Drug companies / Fingolimod
Fingolimod: 18 companies and 18 products in the FDA NDC directory
Fingolimod is listed in the FDA National Drug Code Directory by 18 companies, with 18 products in commercial distribution. 18 of the products (100.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are capsule, and the newest product started marketing on August 27, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 18
- Products
- 18
- Generic (ANDA) products
- 18 (100.0%)
- Application numbers
- 12
- Routes
- Oral
- openFDA record search
- api.fda.gov
Companies that list fingolimod
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Alembic Pharmaceuticals Inc. | 1 | capsule | Generic drugs (ANDA) | April 28, 2026 |
| Alembic Pharmaceuticals Limited | 1 | capsule | Generic drugs (ANDA) | April 28, 2026 |
| Apotex Corp. | 1 | capsule | Generic drugs (ANDA) | October 18, 2022 |
| Aurobindo Pharma Limited | 1 | capsule | Generic drugs (ANDA) | February 28, 2024 |
| AvKARE | 1 | capsule | Generic drugs (ANDA) | February 15, 2024 |
| Biocon Pharma Inc. | 1 | capsule | Generic drugs (ANDA) | March 28, 2024 |
| Camber Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | September 27, 2019 |
| CivicaScript LLC | 1 | capsule | Generic drugs (ANDA) | June 1, 2026 |
| Dr. Reddy's Laboratories Inc. | 1 | capsule | Generic drugs (ANDA) | October 11, 2022 |
| Glenmark Pharmaceuticals Inc., USA | 1 | capsule | Generic drugs (ANDA) | September 28, 2022 |
| Novadoz Pharmaceuticals LLC | 1 | capsule | Generic drugs (ANDA) | August 27, 2026 |
| Quallent Pharmaceuticals Health LLC | 1 | capsule | Generic drugs (ANDA) | March 28, 2024 |
| Solco Healthcare US, LLC | 1 | capsule | Generic drugs (ANDA) | February 17, 2020 |
| Sun Pharmaceutical Industries, Inc. | 1 | capsule | Generic drugs (ANDA) | October 25, 2022 |
| Teva Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | February 14, 2024 |
| XLCare Pharmaceuticals, Inc. | 1 | capsule | Generic drugs (ANDA) | June 17, 2024 |
| Zydus Lifesciences Limited | 1 | capsule | Generic drugs (ANDA) | October 11, 2022 |
| Zydus Pharmaceuticals USA Inc. | 1 | capsule | Generic drugs (ANDA) | October 11, 2022 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 18 | 100% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 18 | 100% |
Pharmacologic classes
| Class | Products |
|---|---|
| Sphingosine 1-phosphate Receptor Modulator | 18 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.